A 62-year-old man presented with a 2-year history of syncope, collapse and fluctuating blood pressure (BP). His medications included midodrine (10 mg, three times per day) and fludrocortisone (0.1 mg, two times per day), but neither treatment afforded symptomatic relief. Autonomic testing was performed. Head-up tilt table testing revealed a supine BP of 112/68 mm Hg (heart rate, 74 beats per minute (bpm)) after 6 min, which dropped to 76/60 mm Hg (83 bpm) within 2 min of 80° head-up tilt. Findings from a heart rate with deep breathing test and a Valsalva test were consistent with autonomic dysfunction. The patient was diagnosed with neurogenic orthostatic hypotension and treated with droxidopa (100 mg, two times per day; titrated to 100 mg, one time per day). After initiating treatment with droxidopa, the patient no longer reported losing consciousness on standing and experienced improvement in activities of daily living. These improvements were maintained through 1 year of follow-up.
- clinical diagnostic tests
- cardiovascular system
- neurology (drugs and medicines)
- medical management
- clinical neurophysiology
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Statistics from Altmetric.com
- clinical diagnostic tests
- cardiovascular system
- neurology (drugs and medicines)
- medical management
- clinical neurophysiology
Syncope can have a variety of aetiologies and may result in falls and associated injuries.1 2
Syncope is defined as a sudden yet transient complete loss of consciousness in which the individual is unable to maintain postural tone, followed by rapid and spontaneous recovery.3 4
Standing for 2 to 3 min is usually sufficient to see the fall in blood pressure (BP) associated with syncope, however in the case presented here, BP was measured after 5 min of standing.4 Determining the underlying cause of syncopal episodes is an important diagnostic step to appropriately guide management (table 1). A relatively common cause of syncope is orthostatic hypotension (OH), which is a drop in BP of ≥20 mm Hg systolic or ≥10 mm Hg diastolic within a few minutes of standing.1 5
Neurogenic OH (nOH; that is, OH resulting from autonomic dysfunction) can be differentiated from non-neurogenic causes of OH (eg, hypovolaemia) clinically by autonomic function tests and by an insufficient compensatory heart rate (HR) increase on standing.6 7 Common clinical signs and symptoms of nOH include dizziness, lightheadedness, syncope and falls.8 Neurogenic OH is commonly comorbid with other disorders associated with autonomic dysfunction, including Parkinson’s disease (PD), multiple system atrophy, pure autonomic failure, dementia with Lewy bodies and type 2 diabetes.6 9 Neurogenic OH increases the risk of falls, which in turn interferes with activities of daily living and increases the burden of symptoms for patients and their caregivers.1 10 11
In those cases in which the aetiology of a patient’s syncope is unclear after initial evaluation and an ECG has ruled out a cardiac cause of syncope, referral for autonomic testing may aid in pinpointing the cause and guide decisions of the most appropriate steps in treating and managing the symptoms of the patient.2 12 In this context, autonomic testing should include continuous BP monitoring during prolonged head-up tilt (HUT) on a tilt table, HR in response to paced breathing and BP in response to the Valsalva manoeuvre.2 12 Decreased autonomic function, if observed, in this battery of tests indicates a neurogenic origin of OH and that the syncope is neurally mediated. Such a diagnosis should suggest a course of treatment.8 12
When the cause of syncope has been identified as OH or nOH, pharmacological management of the condition may be necessary.8 Droxidopa, a norepinephrine prodrug, is the only drug currently approved by the US Food and Drug Administration to treat symptoms of nOH in adults,8 13 whereas midodrine, an alpha−1 adrenergic agonist, is approved to treat symptoms of OH.14
A 62-year-old man was evaluated for a 2-year history of syncope, collapse and fluctuating BP. His medical history included Hodgkin lymphoma, lupus, type 2 diabetes mellitus, autonomic neuropathy, hypercholesterolaemia, hypothyroidism and orthostatic hypotension. He was being treated with gabapentin (300 mg, two times per day, saxagliptin (5 mg, one time per day (QD)), pravastatin (40 mg QD), levothyroxine sodium (100 mg QD), omeprazole (20 mg QD), prednisone (10 mg, every other day), midodrine (10 mg, three times per day) and fludrocortisone (0.1 mg two times per day).
At the time of his initial evaluation, the patient reported that his syncope was progressively worse over the past 3 months. Although his episodes of syncope were previously preceded by dizziness and nausea, they had begun to occur without warning. He also reported a 5-year history of orthostatic hypotension, with a supine BP of approximately 100/66 mm Hg and a standing BP as low as 50/40 mm Hg. His low standing BP and episodes of syncope persisted despite daily treatment with fludrocortisone and midodrine. Initial cardiac evaluation revealed a systolic murmur but was otherwise unremarkable. Other than OH, a clinical manifestation of possible cardiovascular autonomic dysfunction, no other signs of autonomic dysfunction were noted during examination (table 2). Additionally, the patient showed no signs of hypovolaemia (ie, extremities were not cold, moist mucous membranes, no increase in urine specific gravity) or of amyloidosis (ie, lack of tongue swelling). Negative findings on serum protein electrophoresis and fat pad biopsy confirmed the lack of amyloidosis.
Autonomic function testing was performed to determine whether the OH was neurogenic in origin. Tilt table testing revealed a BP drop from 112/68 mm Hg (HR, 74 bpm) after 6 min in the supine position to 76/60 mm Hg (83 bpm) within 2 min of tilt to the 80° head-up position; this BP drop was accompanied by dizziness and weakness at 2 min of tilt and presyncope at 4 min of tilt. Continuous recording with transcranial Doppler during tilt testing indicated no changes in mean cerebral blood flow. ECG tracings during the HR with deep breathing test (paced breathing at six breaths per minute) showed an expiration/inhalation ratio of 1.02, which is abnormal for the patient’s age and sex, indicating depressed baseline autonomic tone and decreased vagal tone. Valsalva testing (measured at 40 mm Hg) revealed a Valsalva ratio of 1.15, which is also abnormal for the patient’s age and sex. Taken together, the results of autonomic testing were consistent with a diagnosis of idiopathic nOH for this patient.
The patient was prescribed droxidopa (100 mg two times per day) to treat symptoms of nOH. Treatment with droxidopa was reduced to 100 mg QD because of nocturnal hypertension, for which he was prescribed a nitroglycerin patch as needed (0.2 mg, transdermal). The patient continued to take both fludrocortisone and midodrine.
Outcome and follow-up
After initiating treatment with droxidopa, the patient reported he no longer lost consciousness on standing, although he still experienced some symptoms of presyncope, such as lightheadedness. One year after initiating droxidopa treatment, these improvements were maintained. The mitigation of his symptoms has improved his activities of daily living and decreased the burden of nOH on both the patient and his caregivers.
Determination of the underlying mechanism of syncope is critical for choosing an appropriate treatment and management protocol.12 A proposed diagnostic algorithm should include a detailed patient history and physical examination (including supine and standing BP measurements and an ECG; figure 1).12 If determination of the mechanism of syncope is inconclusive after initial examinations, then autonomic function testing is warranted.2 12
The underlying causes of nOH can be varied, and there are multiple factors to be considered in the management of nOH, especially in the face of comorbid conditions. A case report identified amyloidosis as a potential cause in a patient who presented with autonomic nervous system impairment and OH with systemic organ involvement including gastrointestinal and kidney dysfunction.15 In two other case reports, patients with PD and cardiac conditions presented with dizziness, lightheadedness and fatigue, and were subsequently diagnosed with nOH.16 17 In one of these cases, the patient was initially suspected to have bradycardia because the symptoms overlap with those seen in nOH and was referred for a pacemaker before diagnostic testing for nOH was even considered.16 Thus, it is imperative for clinicians to screen for nOH when patients present with non-specific symptoms like dizziness and lightheadedness, even when there are other comorbidities present.
Autonomic function testing, including HUT, HR with deep breathing and response to the Valsalva manoeuvre, can determine whether orthostatic syncope is neurogenic in origin.2 12
Although the standard supine-to-standing BP test is more commonly used and can be performed in many clinical settings, HUT testing on a tilt table has several advantages.8 When secured to the tilt table, HUT is markedly safer for patients who experience syncope on standing.2 Passive HUT eliminates the potential confound of compensatory muscle contraction, leading to a more sensitive test.2 Abnormal response to the HR with deep breathing test or to the Valsalva manoeuvre indicates autonomic dysfunction is likely causing orthostatic symptoms. In the current case, autonomic testing led to an efficient diagnosis of nOH, which allowed for implementation of appropriate pharmacological intervention.
When the first treatment for nOH does not relieve symptom burden, it is important to continue to seek a symptom-alleviating treatment.8 The goal of treatment is to restore physical capabilities and reduce potentially dangerous symptoms, not to normalise BP.8 The patient in this case study experienced improved quality of life once his symptoms were successfully treated with droxidopa.
My father’s case had a slow process. I’m not sure how long he had this, because his symptoms began around the same time he was diagnosed with cancer in 2011. It continued to happen even after chemo. His blood pressure would get really low. He lost his brother in a motorcycle accident. We thought maybe the trauma or stress was causing his blood pressure to go crazy. Medications to control his blood pressure were not helping. He was taking three medications, and they were not even gapping the bridge. Another physician thought it could be postural orthostatic tachycardia syndrome, which is why my father was referred to The Heartbeat Clinic. They wanted to do tests to be sure about the diagnosis before any medication was prescribed. We couldn’t even walk from the car to the office without my dad going down and passing out. He couldn’t even use the restroom without passing out. He had broken ribs and busted his head open from passing out and falling. He passed out six to seven times per day. My mom would try to get him to a chair real quick. We needed to lift his legs to get his blood circulating, but my mother is small and couldn’t get him off the floor. By the time he turned 60, he was forced to retire because his health was so awful. His doctor provided albumin and intravenous fluids, which would last for about a week or 2 weeks. We were going to McKinney (The Heartbeat Clinic) a lot. That’s when we finally got the diagnosis of neurogenic orthostatic hypotension. The first dose shot his BP up, so they brought it down to 100 mg. He doesn’t have a normal life because his BP still gets low, but he no longer passes out several times per day.
If we could help somebody else by sharing this story, that would be wonderful. My father’s quality of life taking no medication was just awful. Is it perfect? By no means not, but I believe he would not be here with us today without this treatment. He can at least function in his home. He needed to get used to using a wheelchair on outings. We do the (nitroglycerin) patches at night if his blood pressure is really high. My advice to patients and families is if you take it slowly you can figure out what works best for you. My father’s quality of life has been so much better than when we started this journey.
My advice for doctors is please don’t tell patients there’s no hope. Pretty much everyone gave up hope on my dad. My thing is, please, as a doctor, please do everything in your power to figure out what you can do and send patients to another doctor if you can’t figure out what to do. Please continue to do testing.
If we could impact somebody’s life…I can’t explain how horrific this was at that time, how scary to wonder if he was going to wake up. It means so much to have doctors that fight for you. You do get to a point in your life where it’s so hopeless. I can’t even imagine what my dad felt. ‘I’m not going to last much longer’; that was his thinking. Until we found The Heartbeat Clinic it was bleak and pretty hopeless. I don’t want anyone else to feel alone.
Orthostatic hypotension is a common cause of syncope and can be identified through orthostatic blood pressure measurements.
A blood pressure drop of ≥20 mm Hg systolic or ≥10 mm Hg diastolic within a few minutes of standing (or head-up tilt) accompanied by little or no increase in heart rate is suggestive of neurogenic orthostatic hypotension.
Although patient history and physical examination findings may be helpful in the diagnostic process for neurogenic orthostatic hypotension, autonomic function testing can provide more definitive information to facilely diagnose the condition.
If non-pharmacological measures and initial pharmacotherapy are ineffective in reducing symptoms of neurogenic orthostatic hypotension, it is critical for patient safety and quality of life that healthcare practitioners continue to seek an effective treatment to reduce symptoms, syncope events and fall risks.
Medical writing assistance was provided by the CHC Group (North Wales, PA, USA). The editorial assistance was funded by Lundbeck.
Contributors SBA, WA and AS contributed to the acquisition, analysis and interpretation of data; participated in drafting the manuscript; critically revised the manuscript for intellectual content and approved the final version of the manuscript for publication. All authors agree to be accountable for the article and to ensure that all questions regarding the accuracy or integrity of the article are investigated and resolved.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests SBA received support from Lundbeck for travel and registration fees. WA has nothing to disclose. AS has received honoraria for serving on advisory boards for Lundbeck.
Provenance and peer review Not commissioned; externally peer reviewed.
Patient consent for publication Obtained.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.